|Day Low/High||49.10 / 50.26|
|52 Wk Low/High||44.30 / 70.05|
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
This is the kind of reversal that happens in a bull market.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.
Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
It becomes difficult for me to tell you where to run in these markets...
There is clear divergence between the best and the worst performers in each sector this earnings season.
Diagnostic firms can have an advantage of recurring revenue streams.
Let's take a fresh look at the charts.
* The Cohen plea is a potentially serious threat to the Presidency and to the Bull Market * The Manafort and Cohen indictments are a blow to the Republican Party and raises the odds of a "Blue Wave" in November * Though the market did well under Pre...
The answer is plenty, but you can't trade that.
Harley-Davidson is among these names showing technical reversal patterns over the past week.
The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
* In a paperless and cloudy world, are investors and citizens as safe as the markets assume we are? * In a flat, networked and interconnected world, is it even possible for America to be an "oasis of prosperity" and a driver or engine of global econ...
Options spreads aren't tradable with some small biotechs, making shares the only way to play.